High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib

✍ Scribed by Kuiper, J.L.; Heideman, D.A.M.; Thunnissen, E.; van Wijk, A.W.; Postmus, P.E.; Smit, E.F.

• Book ID: 122306021
• Publisher: Elsevier Science
• Year: 2014
• Tongue: English
• Weight: 344 KB
• Volume: 50
• Category: Article
• ISSN: 0959-8049
• DOI: 10.1016/j.ejca.2014.02.005